Published in JAMA Health Forum · View the paper (DOI)
A RAND Corporation study found that the out-of-pocket cost of naloxone increased by more than 500% for those without health insurance, while decreasing for those with coverage. The high cost may be a significant barrier to naloxone adoption among the uninsured, highlighting the need for policymakers to address financial barriers.
Coverage from 2 institutions